Candel Therapeutics Stock In The News

CADL Stock  USD 8.75  0.81  10.20%   
Our overall analysis of Candel Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Candel Therapeutics. The specific impact of Candel Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Candel Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Candel Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Candel Therapeutics Backtesting and Candel Therapeutics Hype Analysis.
For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.

Candel Therapeutics Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
https://www.globenewswire.com/news-release/2025/03/13/3042609/0/en/Candel-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Recent-Corporate-Highlights.html
 Neutral
Macroaxis News: globenewswire.com
Candel Therapeutics Announces Positive F...
https://www.globenewswire.com/news-release/2025/02/25/3031995/0/en/Candel-Therapeutics-Announces-Positive-Final-Survival-Data-from-Randomized-Controlled-Phase-2-Clinical-Trial-of-CAN-2409-in-Non-Metastatic-Pancreatic-Cancer.html
 Bullish
Yahoo News
Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors
https://finance.yahoo.com/news/milestone-pharmaceuticals-appoints-industry-veteran-120000980.html
 Bullish
Yahoo News
7 A-Rated Biotech Stocks Worth Betting on in June
https://finance.yahoo.com/news/7-rated-biotech-stocks-worth-111500984.html
 Bullish
Macroaxis News: globenewswire.com
Candel Therapeutics Announces Restructur...
https://www.globenewswire.com/news-release/2023/11/28/2787049/0/en/Candel-Therapeutics-Announces-Restructuring-to-Prioritize-Resources-on-Key-Value-Drivers-for-Expanded-Development-of-CAN-3110-the-enLIGHTEN-Discovery-Platform-and-Key-Clinical-Read.html
 Neutral
Macroaxis News: globenewswire.com
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
https://www.globenewswire.com/news-release/2023/11/09/2777291/0/en/Candel-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Recent-Corporate-Highlights.html
 Neutral
Macroaxis News: globenewswire.com
Candel Therapeutics Presents Preclinical Data from its enLIGHTENâ„¢ Discovery Platform at SITC
https://www.globenewswire.com/news-release/2023/11/04/2773546/0/en/Candel-Therapeutics-Presents-Preclinical-Data-from-its-enLIGHTEN-Discovery-Platform-at-SITC.html
 Bullish
Macroaxis News: globenewswire.com
Candel Therapeutics Announces Initial Po...
https://www.globenewswire.com/news-release/2023/11/03/2773326/0/en/Candel-Therapeutics-Announces-Initial-Positive-Interim-Data-from-Randomized-Phase-2-Clinical-Trial-of-CAN-2409-in-Non-Metastatic-Pancreatic-Cancer.html
 Neutral
Macroaxis News: globenewswire.com
Candel Therapeutics Announces Nature Pub...
https://www.globenewswire.com/news-release/2023/10/18/2762584/0/en/Candel-Therapeutics-Announces-Nature-Publication-Showing-Extended-Survival-Associated-with-Immune-Activation-in-Patients-with-Recurrent-High-Grade-Glioma-Treated-with-CAN-3110.html
 Neutral
Macroaxis News: globenewswire.com
Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting
https://www.globenewswire.com/news-release/2023/09/27/2750513/0/en/Candel-Therapeutics-Announces-Three-Abstracts-Accepted-for-Poster-Presentations-at-SITC-2023-Annual-Meeting.html
 Neutral

Candel Therapeutics Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Candel and other traded companies coverage with news coverage. We help investors stay connected with Candel headlines for the 15th of March 2025 to make an informed investment decision based on correlating the impacts of news items on Candel Stock performance. Please note that trading solely based on the Candel Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Candel Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Candel Therapeutics investors visualize upcoming and past events in order to time the market based on Candel Therapeutics noise-free hype analysis.
Candel Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Candel earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Candel Therapeutics that are available to investors today. That information is available publicly through Candel media outlets and privately through word of mouth or via Candel internal channels. However, regardless of the origin, that massive amount of Candel data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Candel Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Candel Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Candel Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Candel Therapeutics alpha.

Candel Largest EPS Surprises

Earnings surprises can significantly impact Candel Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-11-12
2021-09-30-0.29-0.260.0310 
2023-08-10
2023-06-30-0.3-0.34-0.0413 
2023-05-11
2023-03-31-0.35-0.30.0514 
2022-11-10
2022-09-30-0.35-0.30.0514 
2022-08-05
2022-06-30-0.41-0.320.0921 
2023-11-09
2023-09-30-0.19-0.31-0.1263 
View All Earnings Estimates

Candel Therapeutics Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Candel Therapeutics Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
news
13th of March 2025
Candel Therapeutics Issues Quarterly Earnings Results
at thelincolnianonline.com 
Gurufocus Stories at Macroaxis
25th of February 2025
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phas...
at gurufocus.com 
news
20th of February 2025
Major Indexes Falter Dow Drops Over 550 Points
at talkmarkets.com 
Google News at Macroaxis
13th of February 2025
Trend Tracker for - Stock Traders Daily
at news.google.com 
Gurufocus Stories at Macroaxis
7th of February 2025
FMR LLCs Strategic Acquisition of Candel Therapeutics Shares
at gurufocus.com 
Google News at Macroaxis
10th of January 2025
Candel therapeutics CMO sells 88,749 in stock - Investing.com
at news.google.com 
Simply Wall St News at Macroaxis
6th of January 2025
Institutions profited after Candel Therapeutics, Inc.s market cap rose US41m last week but...
at simplywall.st 
Macroaxis News
26th of December 2024
Disposition of 50000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 9.01 sub...
at MacroaxisInsider 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Candel Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Candel Therapeutics' short interest history, or implied volatility extrapolated from Candel Therapeutics options trading.
When determining whether Candel Therapeutics is a strong investment it is important to analyze Candel Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Candel Therapeutics' future performance. For an informed investment choice regarding Candel Stock, refer to the following important reports:
Check out Candel Therapeutics Backtesting and Candel Therapeutics Hype Analysis.
For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. If investors know Candel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Candel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.73)
Revenue Per Share
0.001
Return On Assets
(0.52)
Return On Equity
(4.81)
The market value of Candel Therapeutics is measured differently than its book value, which is the value of Candel that is recorded on the company's balance sheet. Investors also form their own opinion of Candel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Candel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Candel Therapeutics' market value can be influenced by many factors that don't directly affect Candel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Candel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Candel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Candel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.